Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Intest Res
Main Authors: Inoue, Nagamu, Kobayashi, Kiyonori, Naganuma, Makoto, Hirai, Fumihito, Ozawa, Morio, Arikan, Dilek, Huang, Bidan, Robinson, Anne M., Thakkar, Roopal B., Hibi, Toshifumi
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Association for the Study of Intestinal Diseases 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478765/
https://ncbi.nlm.nih.gov/pubmed/28670237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2017.15.3.395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados